Abstract：
BACKGROUND: Dupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor alpha subunit, thus blocking the effects of IL-4 and IL-13, and has shown efficacy in treating various conditions including asthma, atopic dermatitis, eosinophilic esophagitis, and others. Because of its immune modulatory effects, clinical trials that studied dupilumab did not allow patients to receive live vaccines during the clinical trials because of an abundance of caution, and thus package inserts recommend that patients who are being treated with dupilumab should avoid live vaccines. Because dupilumab is now approved for use in patients from 6 months of age for the treatment of atopic dermatitis, this reported contraindication is now posing a clinical dilemma for patients and clinicians.
OBJECTIVE: To perform a systematic review of literature on the safety and efficacy of vaccinations in patients who are receiving dupilumab and to provide expert guidance on the use of vaccines in patients who are receiving dupilumab.
METHODS: A systematic review of the literature was performed, and an expert Delphi Panel was assembled.
RESULTS: The available literature on patients who received vaccinations while using dupilumab overall suggests that live vaccines are safe and that the vaccine efficacy, in general, is not affected by dupilumab. The expert Delphi panel agreed that the use of vaccines in patients receiving dupilumab was likely safe and effective.
CONCLUSIONS: Vaccines (including live vaccines) can be administered to patients receiving dupilumab in a shared decision-making capacity.
OBJECTIVE: To perform a systematic review of literature on the safety and efficacy of vaccinations in patients who are receiving dupilumab and to provide expert guidance on the use of vaccines in patients who are receiving dupilumab.
METHODS: A systematic review of the literature was performed, and an expert Delphi Panel was assembled.
RESULTS: The available literature on patients who received vaccinations while using dupilumab overall suggests that live vaccines are safe and that the vaccine efficacy, in general, is not affected by dupilumab. The expert Delphi panel agreed that the use of vaccines in patients receiving dupilumab was likely safe and effective.
CONCLUSIONS: Vaccines (including live vaccines) can be administered to patients receiving dupilumab in a shared decision-making capacity.
摘要：
背景：Dupilumab是一种靶向白细胞介素（IL）-4受体α亚基的单克隆抗体，从而阻断IL-4和IL-13的作用，并已显示出治疗包括哮喘在内的各种疾病的功效，特应性皮炎,嗜酸性粒细胞性食管炎,和其他人。由于其免疫调节作用，研究dupilumab的临床试验出于谨慎考虑，不允许患者在临床试验期间接种活疫苗，因此，包装说明书建议接受dupilumab治疗的患者避免接种活疫苗。由于dupilumab现在被批准用于治疗特应性皮炎至6个月的年龄，这一报道的禁忌症现在给患者和临床医生带来了临床难题.
目的：对接受dupilumab的患者接种疫苗的安全性和有效性的文献进行系统回顾，并为接受dupilumab的患者使用疫苗提供专家指导。
方法：对文献进行了系统回顾，并进行了专家Delphi小组。
结果：关于接受疫苗接种而使用dupilumab的患者的现有文献表明，活疫苗是安全的，疫苗的有效性，总的来说,不受dupilumab的影响。专家Delphi小组同意在dupilumab患者中使用疫苗可能是安全有效的。
结论：疫苗（包括活疫苗）可以以共同的决策能力在dupilumab上给予患者。
目的：对接受dupilumab的患者接种疫苗的安全性和有效性的文献进行系统回顾，并为接受dupilumab的患者使用疫苗提供专家指导。
方法：对文献进行了系统回顾，并进行了专家Delphi小组。
结果：关于接受疫苗接种而使用dupilumab的患者的现有文献表明，活疫苗是安全的，疫苗的有效性，总的来说,不受dupilumab的影响。专家Delphi小组同意在dupilumab患者中使用疫苗可能是安全有效的。
结论：疫苗（包括活疫苗）可以以共同的决策能力在dupilumab上给予患者。
